PMS Registry
Company Name
AbbVie Biopharmaceuticals GmbH
Protocol Number
P20-272
Title of Study
Prospective Observational Cohort study of patients with moderate to severe chronic plaque psoriasis in Taiwan
Primary Objective
To characterize the short-term response of risankizumab compared to other biologics measured by the proportion of patients achieving PASI 90 response at week 24 in adult patients with moderate to severe chronic plaque psoriasis who are naïve or experienced to biological therapy.
Number of Sites
8
Period of Study
From:01-Jan-2021 to:31-Dec-2024
Number of Patients
240人
IRB Approval Date
CGMFLK 28-Apr-2021
CMUH 11-Jan-2021
HLTCH 11-Feb-2021
KMUH 09-Mar-2021
NCKUH 24-Mar-2021
NTUH 26-Feb-2021
NTUH-HsinChu 05-Jul-2021
SHH 25-Feb-2021
Publication Plan / Date
Planned Year 2025